Taiwan cancer drugs developer seeks Hong Kong bond issue ahead of IPO after delisting from Taipei

JHL Biotech, a Taiwan developer of cheaper alternatives to patent-protected biological drugs, has raised US$106 million from a convertible bond issue, ahead of its planned Hong Kong initial public offering (IPO) aiming to raise some US$250 million.
( read original story …)


Related Post

McKinsey’s Kevin Sneader on rebooting the consulta...
views 9
Leading McKinsey, which advises the world’s bigges...
Hong Kong’s leader to meet China vice-premier in B...
views 9
Hong Kong’s leader Carrie Lam Cheng Yuet-ngor will...
Second Hong Kong film on mainland China’s ‘709’ hu...
views 10
Jin’s plight and thoughts, along with other untold...
Egyptian Coptic Christian couple went on hunger st...
views 16
A Coptic Christian couple who say they are fleeing...
BOC Hong Kong eyes Asian expansion
views 16
Hoping to take advantage of the growing wealth in ...
Hong Kong’s elderly prisoner population has nearly...
views 16
Hong Kong prisons are struggling to cope with an a...
Xiaomi seeks to raise up to $6 billion in Hong Kon...
views 27
SEOUL, Korea, Republic Of — Chinese smartphone mak...
Hong Kong’s electric dream a step closer as China’...
views 28
Hong Kong wants to lure new business to the city b...
Xiaomi seeks to raise up to $6.1 billion in Hong K...
views 28
Xiaomi Corp. plans to raise up to $6.1 billion in ...
Outgoing Hong Kong science park boss Fanny Law has...
views 28
News this month of her stepping down as head of th...